Table 2.
Other hormones assessed during follow up after pembrolizumab administration
| Variables | 21/04/22 | 24/04/22 | 27/04/22 | 03/05/22 |
|---|---|---|---|---|
| LH (normal range 1.8-11.78) (mIU/mL) | 1.09 | PA | 1.03 | 0.94 |
| FSH (normal range 3.03-8.08) (mIU/mL) | 3.74 | 4.3 | 3.48 | |
| Oestradiol (normal range 21-251) (pg/mL) | 20 | 21 | 28 | |
| Prolactin (normal range 5.18-26.53) (ng/mL) | 47.53 | 40.27 | 33.72 | |
| TSH (normal range 0.35-4.94) (mcIU/mL) | 9.37 | |||
| Free T4 (normal range 0.7-1.48) (ng/dL) | 1.01 | |||
| GH (normal range < 8) (ng/mL) | 5.4 | 13.5 | 3.08 | |
| IGF-1 (normal range for ages 83-259) (ng/mL) | 556 | 52 | 41.6 |
LH: luteinizing hormone; FSH: follicle-stimulating hormone; TSH: thyroid-stimulating hormone; GH: growth hormone; IGF-1: insulin-like growth factor 1; PA: pembrolizumab administration.